{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T13:23:08Z","timestamp":1794576188223,"version":"4.9.1"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100032286","name":"Sinocelltech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100032286","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013076","name":"National Major Science and Technology Projects of China","doi-asserted-by":"publisher","award":["2018ZX09736002"],"award-info":[{"award-number":["2018ZX09736002"]}],"id":[{"id":"10.13039\/501100013076","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Therapeutic Research"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.curtheres.2026.100848","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:41:13Z","timestamp":1790811673000},"page":"100848","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Population pharmacokinetic modeling of adalimumab biosimilar SCT630 and Humira\u00ae in healthy participants and patients with moderate to severe plaque psoriasis to establish PK similarity"],"prefix":"10.1016","volume":"105","author":[{"given":"Dongyang","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhuan","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyun","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianqian","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangzhi","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.curtheres.2026.100848_bib0001","unstructured":"U.S. Food and Drug Administration. Approval Letter: Humira (adalimumab). BLA 125057. December 31, 2002.Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2002\/BLA_125057_S000_HUMIRA_APPROV.PDF."},{"key":"10.1016\/j.curtheres.2026.100848_bib0002","unstructured":"European Medicines Agency. Humira: EPAR - Medicine overview. European Medicines Agency. Updated October 8, 2025. Accessed October 8, 2026, available at: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/humira."},{"key":"10.1016\/j.curtheres.2026.100848_bib0003","unstructured":"European Medicines Agency. Guideline on similar biological medicinal products. CHMP\/437\/04 Rev 1. October 23, 2014. Accessed October 8, 2026."},{"key":"10.1016\/j.curtheres.2026.100848_bib0004","unstructured":"Public Health Service Act \u00a7 351(k), 42 USC \u00a7 262(k) (2010)."},{"issue":"5","key":"10.1016\/j.curtheres.2026.100848_bib0005","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1111\/bcp.12656","article-title":"Biosimilar: what it is not","volume":"80","author":"de Mora","year":"2015","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.curtheres.2026.100848_bib0006","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1007\/s12325-024-02818-9","article-title":"Relevance of adalimumab product attributes to patient experience in the biosimilar era: a narrative review","volume":"41","author":"Allegretti","year":"2024","journal-title":"Adv Ther"},{"key":"10.1016\/j.curtheres.2026.100848_bib0007","unstructured":"National Medical Products Administration (NMPA). An Jia Run\u00ae (adalimumab injection) label, Published November 24, 2023. Accessed October 8, 2026, available at: https:\/\/www.cde.org.cn\/main\/xxgk\/postmarketpage?acceptidCODE=11a3312dfce478f7df99f337a9f40e2f."},{"key":"10.1016\/j.curtheres.2026.100848_bib0008","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.2147\/DDDT.S317382","article-title":"An update review of biosimilars of adalimumab in psoriasis - bioequivalence and interchangeability","volume":"15","author":"Zhou","year":"2021","journal-title":"Drug Des Devel Ther"},{"issue":"1","key":"10.1016\/j.curtheres.2026.100848_bib0009","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.dmpk.2018.11.004","article-title":"Biosimilarity assessment of biosimilar therapeutic monoclonal antibodies","volume":"34","author":"Ishii-Watabe","year":"2019","journal-title":"Drug Metab Pharmacokinet"},{"issue":"1","key":"10.1016\/j.curtheres.2026.100848_bib0010","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.xphs.2018.10.053","article-title":"Role of Modeling and simulation in the development of novel and biosimilar therapeutic proteins","volume":"108","author":"Wang","year":"2019","journal-title":"J Pharm Sci"},{"issue":"6","key":"10.1016\/j.curtheres.2026.100848_bib0012","doi-asserted-by":"crossref","first-page":"702","DOI":"10.3390\/pharmaceutics16060702","article-title":"Population Pharmacokinetic analysis and simulation of alternative dosing regimens for biosimilars to adalimumab and etanercept in patients with rheumatoid arthritis","volume":"16","author":"Ling","year":"2024","journal-title":"Pharmaceutics"},{"issue":"5","key":"10.1016\/j.curtheres.2026.100848_bib0013","doi-asserted-by":"crossref","first-page":"499","DOI":"10.17219\/acem\/145947","article-title":"Comparative assessment of pharmacokinetic parameters between HS016, an adalimumab biosimilar, and adalimumab (Humira\u00ae) in healthy subjects and ankylosing spondylitis patients: population pharmacokinetic modeling","volume":"31","author":"Zeng","year":"2022","journal-title":"Adv Clin Exp Med"},{"issue":"11","key":"10.1016\/j.curtheres.2026.100848_bib0014","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1111\/bcp.14330","article-title":"Population pharmacokinetics of adalimumab biosimilar adalimumab-adbm and reference product in healthy subjects and patients with rheumatoid arthritis to assess pharmacokinetic similarity","volume":"86","author":"Kang","year":"2020","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.curtheres.2026.100848_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.108599","article-title":"Phase I, randomized, double-blind, single-dose study to assess the pharmacokinetics, safety, and immunogenicity of the proposed biosimilar SCT630 and adalimumab in healthy Chinese subjects","volume":"106","author":"Liu","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.curtheres.2026.100848_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.109248","article-title":"A randomized, double-blind phase III study to demonstrate the clinical similarity of biosimilar SCT630 to reference adalimumab in Chinese patients with moderate to severe plaque psoriasis","volume":"112","author":"Yu","year":"2022","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"10.1016\/j.curtheres.2026.100848_bib0017","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.clinthera.2021.11.016","article-title":"Establishing PK equivalence between adalimumab and ABP 501 in the presence of antidrug antibodies using population PK modeling","volume":"44","author":"Doshi","year":"2022","journal-title":"Clin Ther"},{"issue":"3","key":"10.1016\/j.curtheres.2026.100848_bib0018","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/jdv.13884","article-title":"Impact of immunogenicity on pharmacokinetics, efficacy and safety of adalimumab in adult patients with moderate to severe chronic plaque psoriasis","volume":"31","author":"Mostafa","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"9","key":"10.1016\/j.curtheres.2026.100848_bib0019","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1007\/s40262-016-0502-4","article-title":"Population pharmacokinetics and immunogenicity of adalimumab in adult patients with Moderate-to-Severe hidradenitis suppurativa","volume":"56","author":"Nader","year":"2017","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"10.1016\/j.curtheres.2026.100848_bib0020","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1023\/A:1012299115260","article-title":"Ways to fit a PK model with some data below the quantification limit","volume":"28","author":"Beal","year":"2001","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"7","key":"10.1016\/j.curtheres.2026.100848_bib0021","doi-asserted-by":"crossref","DOI":"10.1038\/psp.2013.26","article-title":"Establishing best practices and guidance in population modeling: an experience with an internal population pharmacokinetic analysis guidance","volume":"2","author":"Byon","year":"2013","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"1","key":"10.1016\/j.curtheres.2026.100848_bib0022","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1080\/14712598.2021.1851362","article-title":"Similar efficacy, safety, and immunogenicity of the biosimilar BI 695501 and adalimumab reference product in patients with moderate-to-severe chronic plaque psoriasis: results from the randomized Phase III VOLTAIRE-PSO study","volume":"21","author":"Menter","year":"2021","journal-title":"Expert Opin Biol Ther"},{"issue":"2","key":"10.1016\/j.curtheres.2026.100848_bib0023","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/bjd.18220","article-title":"AURIEL-PsO: a randomized, double-blind phase III equivalence trial to demonstrate the clinical similarity of the proposed biosimilar MSB11022 to reference adalimumab in patients with moderate-to-severe chronic plaque-type psoriasis","volume":"182","author":"Hercogov\u00e1","year":"2020","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.curtheres.2026.100848_bib0024","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.jaad.2016.12.014","article-title":"Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: a randomized, double-blind, multicenter, phase III study","volume":"76","author":"Papp","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.curtheres.2026.100848_bib0025","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s12325-021-01899-0","article-title":"Efficacy and Safety of HLX03, an adalimumab biosimilar, in patients with moderate-to-severe plaque psoriasis: a randomized, double-blind, phase III study","volume":"39","author":"Cai","year":"2022","journal-title":"Adv Ther."},{"issue":"6","key":"10.1016\/j.curtheres.2026.100848_bib0026","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s40259-021-00502-w","article-title":"Efficacy, Safety and immunogenicity of AVT02 versus originator adalimumab in subjects with moderate to severe chronic plaque psoriasis: a multicentre, Double-Blind, randomised, parallel group, active control, Phase III study","volume":"35","author":"Feldman","year":"2021","journal-title":"BioDrugs"},{"issue":"1","key":"10.1016\/j.curtheres.2026.100848_bib0027","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1186\/s13075-021-02626-4","volume":"23","author":"Fleischmann","year":"2021","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"10.1016\/j.curtheres.2026.100848_bib0028","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s40259-016-0174-5","article-title":"Assessing the immunogenicity of biopharmaceuticals","volume":"30","author":"Pineda","year":"2016","journal-title":"BioDrugs"},{"key":"10.1016\/j.curtheres.2026.100848_bib0029","unstructured":"Humira (adalimumab) injection, for subcutaneous use. Prescribing information. AbbVie Inc; 2025. Accessed October 8, 2026. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/125057s425lbl.pdf."},{"issue":"9","key":"10.1016\/j.curtheres.2026.100848_bib0030","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1111\/bcp.13996","article-title":"Evaluation of covariate effects on pharmacokinetics of monoclonal antibodies in oncology","volume":"85","author":"Bajaj","year":"2019","journal-title":"Br J Clin Pharmacol"},{"issue":"7","key":"10.1016\/j.curtheres.2026.100848_bib0031","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1007\/s40262-020-00874-2","article-title":"Pharmacokinetic variability of therapeutic antibodies in humans: a comprehensive review of population pharmacokinetic modeling publications","volume":"59","author":"Bensalem","year":"2020","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"10.1016\/j.curtheres.2026.100848_bib0032","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1007\/s12325-024-03100-8","article-title":"Repeated switching between CT-P17 and EU reference adalimumab in patients with moderate-to-severe chronic plaque psoriasis: a randomized, Double-Blind, Active-Controlled, Phase 3, interchangeability study","volume":"42","author":"Lebwohl","year":"2025","journal-title":"Adv Ther"},{"issue":"12","key":"10.1016\/j.curtheres.2026.100848_bib0033","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1080\/13543784.2016.1255724","article-title":"Bioequivalence, safety and immunogenicity of BI 695501, an adalimumab biosimilar candidate, compared with the reference biologic in a randomized, double-blind, active comparator phase I clinical study (VOLTAIRE\u00ae-PK) in healthy subjects","volume":"25","author":"Wynne","year":"2016","journal-title":"Expert Opin Investig Drugs"}],"container-title":["Current Therapeutic Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0011393X26000299?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0011393X26000299?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T12:23:20Z","timestamp":1794572600000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0011393X26000299"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":32,"alternative-id":["S0011393X26000299"],"URL":"https:\/\/doi.org\/10.1016\/j.curtheres.2026.100848","relation":{},"ISSN":["0011-393X"],"issn-type":[{"value":"0011-393X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Population pharmacokinetic modeling of adalimumab biosimilar SCT630 and Humira\u00ae in healthy participants and patients with moderate to severe plaque psoriasis to establish PK similarity","name":"articletitle","label":"Article Title"},{"value":"Current Therapeutic Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.curtheres.2026.100848","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100848"}}